 |
BioWorld-Insight-2003-05-12
Stock Winners and Losers For The Week
Non-U.S. Clinical Trials, Regulatory Submissions, Recommendations And Approvals: April 2003
No Abstract
Survey: Price Key In ED Race As Firms Vie To Steal Viagra Market
What a difference a year makes. Or not.
At this point in 2002, ICOS Corp. had just received word from the FDA that its erectile dysfunction drug candidate Cialis (taladifil), partnered with Eli Lilly and Co., was approvable if three issues were cleared up. (See BioWorld Financial Watch, May 6, 2002.)